Chapter title |
Current Topical and Systemic Therapies for Itch.
|
---|---|
Chapter number | 18 |
Book title |
Pharmacology of Itch
|
Published in |
Handbook of experimental pharmacology, January 2015
|
DOI | 10.1007/978-3-662-44605-8_18 |
Pubmed ID | |
Book ISBNs |
978-3-66-244604-1, 978-3-66-244605-8
|
Authors |
Leslie, Tabi Anika, Greaves, Malcolm W, Yosipovitch, Gil, Tabi Anika Leslie, Malcolm W. Greaves, Gil Yosipovitch, Greaves, Malcolm W. |
Abstract |
Itch is a common distressing symptom which may be caused by multifactorial aetiologies including inflammatory skin diseases, systemic diseases, neuropathic conditions and psychogenic disorders. Itch is a term used synonymously with pruritus and is defined as acute if it lasts less than 6 weeks or chronic if it persists for more than 6 weeks. It can have the same impact on the quality of life as chronic pain and shares many of the same pathophysiological pathways. Depending on the aetiology of the itch, different pathogenic mechanisms have been postulated with a number of mediators identified. These include histamine, leukotrienes, proteases, neuropeptides, cytokines and opioids, which may activate peripheral itch-mediating C-fibres via receptors on the nerve terminals and central neuronal pathways. Therefore, there is no single universally effective anti-itch treatment available. First-line treatments for itch include topical therapies, such as emollients, mild cleansers (low pH), topical anaesthetics, steroids, calcineurin inhibitors and coolants (menthol). Treatment with systemic therapies can vary according to the aetiology of the chronic itch. Non-sedating antihistamines are helpful in conditions such as urticaria where the itch is primarily histamine mediated. Although the itch of eczema is not mediated by histamine, sedating antihistamines at night are helpful to break the itch-scratch cycle. Chronic itch may also be treated with other systemic therapies, such as anticonvulsants, antidepressants as well as mu-opioid antagonists, kappa-opioid agonists and phototherapy, depending on the cause of the itch. This article summarises the topical and systemic therapies available with our current understanding of the pathophysiology of itch. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Romania | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 1 | 50% |
Members of the public | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Germany | 1 | 2% |
Unknown | 61 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 9 | 15% |
Student > Doctoral Student | 8 | 13% |
Other | 7 | 11% |
Student > Ph. D. Student | 6 | 10% |
Student > Bachelor | 5 | 8% |
Other | 11 | 18% |
Unknown | 16 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 25 | 40% |
Agricultural and Biological Sciences | 4 | 6% |
Psychology | 3 | 5% |
Biochemistry, Genetics and Molecular Biology | 3 | 5% |
Unspecified | 2 | 3% |
Other | 8 | 13% |
Unknown | 17 | 27% |